Role of miR-2392 in driving SARS-CoV-2 infection

Adult Male QH301-705.5 antiviral therapeutic Antiviral Agents Article Mice Cricetinae Animals Humans Biology (General) Hypoxia miRNA Aged Aged, 80 and over Inflammation microRNA SARS-CoV-2 miR-2392 Ferrets COVID-19 Middle Aged Healthy Volunteers 3. Good health MicroRNAs nanoligomers Gene Expression Regulation biomarker Female Glycolysis Biomarkers
DOI: 10.1016/j.celrep.2021.109839 Publication Date: 2021-09-30T04:34:14Z
ABSTRACT
MicroRNAs (miRNAs) are small non-coding RNAs involved in post-transcriptional gene regulation that have a major impact on many diseases and provide an exciting avenue toward antiviral therapeutics. From patient transcriptomic data, we determined that a circulating miRNA, miR-2392, is directly involved with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) machinery during host infection. Specifically, we show that miR-2392 is key in driving downstream suppression of mitochondrial gene expression, increasing inflammation, glycolysis, and hypoxia, as well as promoting many symptoms associated with coronavirus disease 2019 (COVID-19) infection. We demonstrate that miR-2392 is present in the blood and urine of patients positive for COVID-19 but is not present in patients negative for COVID-19. These findings indicate the potential for developing a minimally invasive COVID-19 detection method. Lastly, using in vitro human and in vivo hamster models, we design a miRNA-based antiviral therapeutic that targets miR-2392, significantly reduces SARS-CoV-2 viability in hamsters, and may potentially inhibit a COVID-19 disease state in humans.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (118)
CITATIONS (71)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....